%0 Clinical Trial Protocol
%T Belgian Endothelial Surgical Transplant of the Cornea (BEST cornea) protocol: clinical and patient-reported outcomes of Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK) versus Descemet Membrane Endothelial Keratoplasty (DMEK) - a multicentric, randomised, parallel group pragmatic trial in corneal endothelial decompensation.
%A de Bruyn B
%A Ní Dhubhghaill S
%A Claerhout I
%A Claes K
%A Deconinck A
%A Delbeke H
%A Huizing M
%A Krolo I
%A Muijzer M
%A Oellerich S
%A Roels D
%A Termote K
%A Van den Bogerd B
%A Van Gerwen V
%A Verhaegen I
%A Wisse R
%A Wouters K
%A Consortium TBC
%A Duchesne B
%A Koppen C
%J BMJ Open
%V 13
%N 9
%D 2023 09 15
%M 37714670
%F 3.006
%R 10.1136/bmjopen-2023-072333
%X Corneal blindness is the third most frequent cause of blindness globally. Damage to the corneal endothelium is a leading indication for corneal transplantation, which is typically performed by lamellar endothelial keratoplasty. There are two conventional surgical techniques: Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK) and Descemet Membrane Endothelial Keratoplasty (DMEK). The purpose of this study is to compare both techniques.<BR>The trial compares UT-DSAEK and DMEK in terms of clinical and patient reported outcomes using a pragmatic, parallel, multicentric, randomised controlled trial with 1:1 allocation with a sample size of 220 participants across 11 surgical centres. The primary outcome is the change in best-corrected visual acuity at 12 months. Secondary outcomes include corrected and uncorrected vision, refraction, proportion of high vision, quality of life (EQ-5D-5L and VFQ25), endothelial cell counts and corneal thickness at 3, 6 and 12 months follow-up appointments. Adverse events will also be compared 12 months postoperatively.<BR>The protocol was reviewed by ethical committees of 11 participating centres with the sponsor centre issuing the final definitive approval. The results will be disseminated at clinical conferences, by patient partner groups and open access in peer-reviewed journals.<BR>Both, trial management group and trial steering committee, are installed with representatives of all stakeholders involved including surgeons, corneal bankers, patients and external experts.<BR>NCT05436665.